We hear a powerful story about the power of MDMA to help heal PTSD.

An FDA advisory committee recently voted against approval of MDMA as a treatment for Post Traumatic Stress Disorder (PTSD), despite extremely promising results from clinical trials. So, in this episode, Molly speaks with Cristina Pearse, founder and CEO of the Protea Foundation, who received MDMA treatment as part of the recent trials. Cristina describes the impact of her childhood trauma as a powerful tsunami. With the help of MDMA-assisted therapy, she says, it became just a puddle at her feet.

Together, we discuss the potential of this medicine, the FDA study design, the recent vote, and the role of advocacy in securing access to this life saving medicine.

If you enjoy Ketamine Insights, please share it with a friend and rate or review it on your favorite podcast platform. Online engagement (ie. ratings and reviews) helps us reach a larger audience.

A New York Times article about the FDA vote on MDMA, which took place on June 4, 2024: https://www.nytimes.com/2024/06/04/health/fda-mdma-therapy-ptsd.html

You can read (MDMA applicant) Lykos' response to the vote here: https://news.lykospbc.com/2024-06-13-Lykos-Therapeutics-Statement-on-FDA-Advisory-Committee-Meeting

Support us and join our community at https://www.patreon.com/ketamineinsights
or at https://mollydunn.substack.com/

Email us at ketamineinsights@gmail.com (we love to hear from you!)

You can also find all of our episodes on YouTube and our website https://ketamineinsights.com/

If you or someone you know is experiencing a mental health crisis, please get help. In the US, you can dial 988. You are never all alone.

As always: Remember to advocate for yourself, and never ration your joy.

Support the show